Cargando…

Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis

Spinal muscular atrophy (SMA) is a disabling disease that affects not only the patient’s health-related quality of life (HRQoL), but also causes a high caregiver burden (CGB). The aim of this study was to evaluate HRQoL, CGB, and their predictors in SMA. In two prospective, cross-sectional, and mult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wohnrade, Camilla, Velling, Ann-Kathrin, Mix, Lucas, Wurster, Claudia D., Cordts, Isabell, Stolte, Benjamin, Zeller, Daniel, Uzelac, Zeljko, Platen, Sophia, Hagenacker, Tim, Deschauer, Marcus, Lingor, Paul, Ludolph, Albert C., Lulé, Dorothée, Petri, Susanne, Osmanovic, Alma, Schreiber-Katz, Olivia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857112/ https://www.ncbi.nlm.nih.gov/pubmed/36672091 http://dx.doi.org/10.3390/brainsci13010110

Ejemplares similares

Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)
por: Mix, Lucas, et al.
Publicado: (2021)

Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy
por: Binz, Camilla, et al.
Publicado: (2022)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
por: Freigang, Maren, et al.
Publicado: (2021)

An observational cohort study on pulmonary function in adult patients with 5q-spinal muscular atrophy under nusinersen therapy
por: Bjelica, Bogdan, et al.
Publicado: (2023)

Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis
por: Osmanovic, Alma, et al.
Publicado: (2020)

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen
por: Wurster, Claudia D., et al.
Publicado: (2019)

Quality of Life in SMA Patients Under Treatment With Nusinersen
por: Mix, Lucas, et al.
Publicado: (2021)

Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy
por: Günther, René, et al.
Publicado: (2019)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
por: Osmanovic, Alma, et al.
Publicado: (2021)

Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy
por: Cordts, Isabell, et al.
Publicado: (2020)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2022)

A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany
por: Peseschkian, Tara, et al.
Publicado: (2021)

Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives
por: Schischlevskij, Pavel, et al.
Publicado: (2021)

Improvement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy
por: Schreiber-Katz, Olivia, et al.
Publicado: (2023)

Economic evaluation of Motor Neuron Diseases: a nationwide cross-sectional analysis in Germany
por: Heinrich, Felix, et al.
Publicado: (2023)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment
por: Binz, Camilla, et al.
Publicado: (2020)

Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy
por: Osmanovic, Alma, et al.
Publicado: (2020)

ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised amyotrophic lateral sclerosis functional rating scale
por: Maier, André, et al.
Publicado: (2022)

Biomarkers in 5q-associated spinal muscular atrophy—a narrative review
por: Lapp, H. S., et al.
Publicado: (2023)

Characterization of cognitive impairment in adult polyglucosan body disease
por: Zebhauser, Paul Theo, et al.
Publicado: (2022)

Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
por: Müschen, Lars Hendrik, et al.
Publicado: (2021)

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
por: Wurster, Claudia D., et al.
Publicado: (2019)

Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany
por: Schönfelder, Erik, et al.
Publicado: (2020)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Maximum bite force in patients with spinal muscular atrophy during the first year of nusinersen therapy – A pilot study
por: Kruse, Teresa, et al.
Publicado: (2020)

Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters
por: Stolte, Benjamin, et al.
Publicado: (2021)

Correction to: Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany
por: Hahn, Andreas, et al.
Publicado: (2022)

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
por: Totzeck, Andreas, et al.
Publicado: (2019)

Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment—A Pilot Study
por: Thimm, Andreas, et al.
Publicado: (2022)

Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2021)

Spinal astrocyte dysfunction drives motor neuron loss in late-onset spinal muscular atrophy
por: Schmitt, Linda-Isabell, et al.
Publicado: (2023)

Induction of Survival of Motor Neuron (SMN) Protein Deficiency in Spinal Astrocytes by Small Interfering RNA as an In Vitro Model of Spinal Muscular Atrophy
por: Leo, Markus, et al.
Publicado: (2022)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_03a8opq34a4eebm07m9ujcpp7p